Eyebright Medical Continues to Employ Its Internationalization Strategy: Signed Memorandum With Invest Hong Kong and Spotlight at ESCRS 2024
Eyebright Medical Continues to Employ Its Internationalization Strategy: Signed Memorandum With Invest Hong Kong and Spotlight at ESCRS 2024
During the signing ceremony for key projects between HONG KONG, Sept. 24, 2024 /PRNewswire/ -- Eyebright Medical Technology (Beijing) Co., Ltd. ("Eyebright Medical", the "Company", Stock Code: 688050.SH, together with its subsidiaries collectively known as the "Group") is pleased to announce the recently development of its internationalization strategy.
北京愛爾明醫療科技有限公司（"北京愛爾明醫療"，"公司"，股票代碼：688050.SH，及其子公司統稱"集團"）很高興宣佈其國際化策略最近的發展。
Eyebright Medical has signed a memorandum of cooperation with the Invest Hong Kong, Leverages Hong Kong as a Platform for Global Expansion
愛爾明醫療與香港投資推廣署簽署合作備忘錄，藉助香港作爲全球擴張平台。
On September 20, Eyebright Medical was invited to the opening ceremony of the 27th Beijing-Hong Kong Economic Cooperation Forum and Investment Promotion Conference.
9月20日，愛爾明醫療受邀參加第27屆北京香港經濟合作論壇暨招商會開幕式。
During the signing ceremony for key projects between Beijing and Hong Kong, Eyebright Medical signed a memorandum of cooperation with the Invest Hong Kong of the Hong Kong Special Administrative Region government.
在北京與香港重點項目簽約儀式上，愛爾明醫療與香港特別行政區政府投資推廣署簽署合作備忘錄。
Eyebright Medical aims to utilize Hong Kong as a platform for its international outreach, establishing it as a base for expanding overseas operations. Invest Hong Kong will provide essential information on the business environment and government policies, along with a suite of support services, including talent acquisition, financing options, and government funding programs.
眼明醫療旨在將香港作爲其國際推廣的平台，將其打造爲擴展海外業務的基地。香港投資推廣署將提供關於商業環境和政府政策的重要信息，以及一系列支持服務，包括人才招聘、融資選擇和政府資助計劃。
Shines on the ESCRS 2024 and Showcasing the Leading R&D Capabilities to the World
在2024年ESCRS（歐洲白內障和屈光手術學會）上大放異彩，展示領先的研發能力給全球。
From September 6 to 10, 2024, Eyebright Medical has participated in the 42nd European Society of Cataract and Refractive Surgeons Congress (ESCRS) showcased its range of self-developed products in cataract surgery, myopia management, and consumer vision care, receiving significant recognition in the global market and reinforcing its commitment to excellence in ophthalmic care. The grand event had attracted over 15,000 participants and facilitating valuable exchanges among leading ophthalmic experts.
2024年9月6日至10日，眼明醫療參加了第42屆歐洲白內障和屈光手術學會大會（ESCRS），展示了其在白內障手術、近視管理和消費視光護理領域的自主研發產品系列，在全球市場獲得了重要認可，並進一步鞏固了其在眼科護理方面卓越的承諾。這一盛會吸引了超過15,000名參與者，並促進了領先眼科專家之間寶貴的交流。
Eyebright Medical's star products, including the monofocal EDOF intraocular lens, multifocal EDOF intraocular lens, and preloaded high-order aspheric intraocular lens series, garnered significant attention at the ESCRS Congress, attracting agents and doctors from around the world eager to learn about and experience these cutting-edge innovations.
眼明醫療的明星產品，包括單焦點EDOF人工晶狀體、多焦點EDOF人工晶狀體和預裝高階非球面人工晶狀體系列，在ESCRS大會上引起了廣泛關注，吸引了來自世界各地渴望了解和體驗這些尖端創新的代理商和醫生。
The monofocal EDOF lens enhances postoperative intermediate and near vision while minimizing visual disturbances, whereas the multifocal EDOF lens offers clear distance and near vision alongside functional intermediate vision, reducing adverse visual phenomena. Additionally, the preloaded intraocular lens features a streamlined one-step operation design that greatly improves surgical efficiency and safety. With corresponding Toric versions available, Eyebright Medical's high-end intraocular lens series effectively meets the personalized selection needs for refractive cataract surgery.
單焦段EDOF晶狀體可增強術後中近視覺，同時減少視覺干擾，而多焦段EDOF晶狀體可提供清晰的遠近視覺以及功能性中間視覺，降低不良的視覺現象。此外，預裝的人工晶狀體具有簡化的一步操作設計，極大提高手術效率和安全性。配備Toric版本，Eyebright Medical的高端人工晶狀體系列有效滿足屈光性白內障手術的個性化選擇需求。
ESCRS has always been an excellent opportunity to share the latest advancements in the field of ophthalmology, learn about innovative products, and connect with peers from around the world. This time, Eyebright Medical showcased its full range of self-developed products at ESCRS, gaining increased attention and recognition in the overseas market. Furthermore, it facilitated in-depth exchanges with international experts and scholars in the field of ophthalmology, discussing cutting-edge technologies and development directions, injecting new momentum into its progress toward becoming a leading international medical enterprise.
歐洲白內障和復明手術協會(ESCRS)一直是分享眼科醫療領域最新進展、了解創新產品並與來自全球的同行建立聯繫的絕佳機會。這次，Eyebright Medical在ESCRS展示了其完整的自主研發產品系列，在境外市場獲得了更多關注和認可。此外，它促進了與眼科醫療領域國際專家和學者深入交流，討論尖端技術和發展方向，爲其成爲領先的國際醫療企業注入新動力。
About Eyebright Medical
Eyebright Meical Technology (Beijing) Ltd ("Eyebright Medical"; SH Stock Code: 688050.SH) is a National High-tech Enterprise and state-level technologically advanced 'little giant' enterprises, located in Zhongguancun Science and Technology Park, Beijing, China.
關於Eyebright Medical
眼明醫療技術（北京）有限公司（「Eyebright Medical」；SH股票代碼：688050.SH）是國家高新技術企業和國家級技術先進「小巨人」企業，位於中國北京中關村科技園區。
The Company is an innovation-driven ophthalmic medical device manufacturer. Its balanced product portfolio spans three major areas of the ophthalmic field: cataract surgery, myopia management, as well as consumer vision care. Anchored by its three core product categories - intraocular lenses, orthokeratology lenses, and soft contact lenses - the company has strategically expanded its product pipeline to cover the full life cycle of eye health solutions. Eyebright Medical is striding into a world-leading medical enterprise on behalf of China's 'intelligent manufacturing' power.
該公司是一家以創新驅動的眼科醫療器械製造商。其平衡的產品組合涵蓋眼科領域的三個主要領域：白內障手術、近視管理以及消費者視力護理。該公司以其三大核心產品類別爲支柱——人工晶體、角膜塑形鏡片和軟性隱形眼鏡——戰略性地擴大了產品管道，涵蓋眼健康解決方案的全部生命週期。在中國「智能製造」實力的支持下，明亮醫療代表中國步入世界領先的醫療企業。
For more information about Eyebright Medical, please visit the official website of the Group: .
有關明亮醫療的更多信息，請訪問集團的官方網站：。
譯文內容由第三人軟體翻譯。